AUTHOR=Kingsley Ryan , Rohlman Christopher , Otto Ashley , Chaudhary Rahul , Phelan David , Kirchoff Robert 

TITLE=Remdesivir-induced conduction abnormalities: A molecular model-based explanation

JOURNAL=Journal of Pharmacy & Pharmaceutical Sciences

VOLUME=26

YEAR=2023

URL=https://www.frontierspartnerships.org/journals/journal-of-pharmacy-pharmaceutical-sciences/articles/10.3389/jpps.2023.11208

DOI=10.3389/jpps.2023.11208

ISSN=1482-1826

ABSTRACT=<p><bold>Purpose:</bold> Remdesivir use in COVID-19 is associated with cardiac conduction abnormalities from unclear mechanisms. A proposed mechanism is the bioaccumulation of the intermediate metabolite GS-441524 resulting in exogenous activation of cardiac adenosine A1 due to the structural similarity between adenosine and GS-441524. The prolonged half-life of GS-441524 can result in sustained activation of adenosine A1 receptors. In this study, we used molecular modeling of adenosine, GS-441524 and the adenosine A1 receptor to assess the potential mechanistic association of the proposed mechanism.</p><p><bold>Methods:</bold> Adenosine and GS-441524 structures were acquired from the PubChem database. Ligand docking was carried out using UCSF Chimera. Models were chosen based on greatest binding affinity and minimum root mean square deviation. Figures of resulting structural models were prepared using UCSF Chimera or PyMOL 2.3.5.</p><p><bold>Results:</bold> By modeling the interaction between the A1 G protein complex and both adenosine and GS-441524, we found that the proposed mechanism of exogenous A1 receptor activation is feasible based on docking compatibility.</p><p><bold>Conclusion:</bold> The proposed mechanism of exogenous cardiac A1 receptor activation from bioaccumulation of GS-441524 as a cause of observed cardiac conduction abnormalities with the use of remdesivir in COVID-19 is viable. Further studies are needed to assess causality.</p>